BioSpace News Archive

FLORHAM PARK, N.J., March 18, 2021 (GLOBE NEWSWIRE) -- Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, announced that the company has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural kille

- FHD-286 Phase 1 data anticipated as early as year-end 2021 - FHD-609 IND submission on track for the second quarter 2021 - Continued advancement of broad therapeutic pipeline targeting the chromatin regulatory system

Positron Corp is pleased to announce that it has retained the services of Skyline Corporate Communications Group, LLC to handle its investor relations and corporate communications activities within the financial community.

Talis Biomedical Corporation, a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, announced the appointment of Jeryl “Jeri” Hilleman to its Board of Directors.

Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2020 after market close on Thursday, March 25, 2021.

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced it will report full year 2020 financial results on Thursday, March 25, 2021 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update.

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that members of the Avadel management team will participate in a fireside chat at Stifel’s Third Annual CNS Day, which is being held on March 31 st .

Gavi, the Vaccine Alliance, Louisville Metro, Ochsner Health, Penn State Health, Piedmont Healthcare and the State of California are using Salesforce technology to help manage their vaccine programs

Veteran Industry Executive joins Delix from Atlas Venture, after previously leading Shire Pharmaceuticals’ Global Neuroscience Business Delix has identified a class of non-hallucinogenic versions of psychedelic compounds, which the company is developing into safer, more effective, treatments for psychiatric and neurological disorders with high unmet needs

Exelixis, Inc. (Nasdaq:EXEL) today announced a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer for the ongoing phase 1b dose escalation study STELLAR-001 (previously called “XL092-001”), adding three new cohorts that will evaluate the safety and tolerability of XL092